Immatics N.V., a clinical-stage biopharmaceutical company, has announced that Bristol Myers Squibb (BMS) will be investing $35 million in the company. BMS acquired 2,419,818 ordinary shares of Immatics through a private placement transaction at a price of $14.461 per share. As part of the investment, BMS also gained the right to appoint a member to the Immatics Scientific Advisory Board. Harpree..
The FDA has four target action dates this week, including approvals for drugs to treat functional constipation, Alagille syndrome, myelofibrosis and symptomatic obstructive hypertrophic cardiomyopathy. Ironwood Pharmaceuticals' Linzess is set to be approved as a treatment for functional constipation in children aged 6-17 years on June 14th. Albireo's Bylvay may also receive approval on June 15th..
AstraZeneca has partnered with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder in a potential deal worth over $2 billion. The collaboration will involve the development of autologous multi-modular Treg cell therapies, which are designed to suppress an overactive immune response seen in organ transplantation, inflammatory and autoimmune disease. As..
AstraZeneca has announced a partnership with Quell Therapeutics to develop cell therapies for Type 1 diabetes and inflammatory bowel disorder. The collaboration involves the use of Quell's T-regulatory (Treg) cell engineering toolbox to develop autologous multi-modular Treg cell therapies, which will be manufactured through to the end of the first-in-human clinical study. AstraZeneca has initial..
AstraZeneca has teamed up with Quell Therapeutics to develop therapies for Type 1 diabetes and inflammatory bowel disorder, potentially putting over $2 billion on the line. AstraZeneca provided $85 million to get started, while the rest of the opportunity comes in the form of development and commercialization milestones and potential royalties down the line. Quell will be responsible for develop..
